However, studies have shown that azacytidine, as a novel antitumor drug, can reduce the proliferation ability of cancer cells by inhibiting DNMT2-mediated m5C modification, suggesting that reducing m5C modification of tRNA may be an effective cancer treatment strategy (Esteller and Pandolfi, 2017). This evidence concerns the gene TRDMT1 and cancer.